Incyte seeks broader Jakafi label

Share this article:

Incyte is working to expand the indication for Jakafi (ruxolitinib), which is currently approved for patients with intermediate or high-risk myelofibrosis.

The company announced Tuesday that it has filed a request that the FDA allow its roster of applications to include patients with polycythemia vera who have had poor response or cannot tolerate hydroxyurea. Polycythemia vera is an overabundance of red blood cells, white blood cells and platelets and is associated with an increased risk of blood clots.

Incyte is also testing the drug among patients with pancreatic cancer, non-small-cell lung cancer, colorectal cancer and breast cancer.

Jakafi earned $84 million in second-quarter sales, an effort that was backed by Incyte's increased investment in its sales force, part of which was in preparation for the anticipated polycythemia vera indication.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.